The Spectrum of Dedicated Stents for Bifurcation Lesions: Current Status and Future Projections. Martin B. Leon, MD

Similar documents
Eulogio Garcia MD H. U. Gregorio Marañon Madrid

Drug Eluting Stents: Bifurcation and Left Main Approach

ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April Session: Left mains & bifurcation intervention

ΣΥΜΠΛΟΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΔΙΧΑΣΜΩΝ

Protection of side branch is essential in treating bifurcation lesions: overview

A Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations

Complex Coronary Interventions: Bifurcations. John M. Lasala MD PhD Professor of Medicine Washington University St Louis, Missouri

LM stenting - Cypher

FFR-guided Jailed Side Branch Intervention

Consensus so far and what we will be focusiong on this time

EBC London 2013 Provisional SB stenting strategy with kissing balloon with Absorb

PCI for Bifurcation Coronary Lesion

The Tryton Side Branch System in Distal Left Main PCI

Welcome to the 8 th European Bifurcation Club October Barcelona

Contemporary therapy of bifurcation lesions

Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD

DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

Bifurcation stenting with BVS

Why I try to avoid side branch dilatation

Medtronic Symposium The Complex Bifurcation Patient: new insights into stent selection

I have nothing to disclose.

Non-LM bifurcation studies of importance in 2011

STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Ενδοςτεφανιαίεσ προκζςεισ (stents):παρόν και μζλλον. Σ Χατηθμιλτιάδθσ Αναπλθρωτισ Κακθγθτισ Πανεπιςτθμιακό Νοςοκομείο ΑΧΕΠΑ

DK Crush,Culotte,SKS,T or TAP. Subhash Chandra, MD,DM,FACC Chairman,Cardiac Sciences BLK Super Speciality Hospital, Pusa Road, New Delhi

Stent Thrombosis in Bifurcation Stenting

Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy

Unprotected LM intervention

Bench Insights into Bifurcation Stenting in the DES Era: An Update

Lessons for technique and stent choice

Y. Louvard, ICPS, Massy, France. TCT Asia Pacific 2010

Complex PCI of an LAD/Diagonal bifurcation lesion (Medina 1,1,1) utilizing the DK Crush technique ".

What Stent to Use? JASVINDAR SINGH MD, FACC

Drug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester

Bifurcation Stenting: IVUS and OCT Information

Dr. Robert J. van Geuns. Thoraxcenter ErasmusMC Rotterdam On behalf of Dr. Jean Fajadet and Co-investigators

COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands

Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program

Integrated Use of IVUS and FFR for LM Stenting

Sideguard dedicated stent system for the treatment of coronary bifurcation artery lesions

Bench test : Is it still useful? Do we need standardization?

IVUS-Guided d Provisional i Stenting: Plaque or Carina Shift. Soo-Jin Kang, MD., PhD.

Insight from Nordic III

September Peter Barlis. Royal Brompton Hospital, London, UK

Count Down to COMBAT

Percutaneous Intervention of Unprotected Left Main Disease

DISCOVER Ultimaster with Optical Frequency Domain Imaging

eluting Stents The SPIRIT Trials

Final Kissing Ballooning Returns? The analysis of COBIS II registry

Dr Aniket Puri. OCT guided BVS for LMCA to LAD : Optimising the 'Pot'

CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer

Nobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy

Session: EBC s position on dedicated devices. Pro

PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France

Drug eluting balloons in CAD

Side Branch Occlusion

TCTAP Upendra Kaul MD,DM,FACC,FSCAI,FAMS,FCSI

Bifurcation Stenting. European Bifurcation Club update. Ioannis Iakovou, MD Onassis Cardiac Surgery Center Athens, Greece

Left Main PCI. Integrated Use of IVUS and FFR. Seung-Jung Park, MD, PhD

Plaque Shift vs. Carina Shift Prevalence and Implication

DES In-stent Restenosis

Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents

PCI for Chronic Total Occlusions

Ultimaster clinical results in left main and bifurcations

PCI for Long Coronary Lesion

PCI for In-Stent Restenosis. CardioVascular Research Foundation

Perspective of LM stenting with Current registry and Randomized Clinical Data

6 th European Bifurcation Club October BUDAPEST. Kissing in simple strategy? Why and how I kiss. Y. Louvard, ICPS, Massy France

Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)

Second Generation Drug Eluting Stents: From Inhibition to Healing

A Novel Low Pressure Self Expanding Nitinol Coronary Stent (vprotect): Device Design and FIH Experience

POLish Bifurcation Optimal treatment Strategy randomized Study (POLBOSS) - Interim analysis

The Nordic Bifurcation Stent Technique Study. A Randomized trial of CRUSH vs CULOTTE Stenting

Update from the Tryton IDE study

A Large Prospective Randomized Trial of DES vs BMS in Patients with STEMI

PCI for Ostial Lesion

eucalimus - First Experience

Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy

For Personal Use. Copyright HMP 2013

The tailored solution for your bifurcation therapy

MULTIVESSEL PCI. IN DRUG-ELUTING STENT RESTENOSIS DUE TO STENT FRACTURE, TREATED WITH REPEAT DES IMPLANTATION

Sunao Nakamura M.D,Ph.D.

Insight from the CACTUS trial Coronary Bifurcation Application of the Crush

OCTOBER. OCT Optimised Bifurcation Event Reduction. A Nordic Baltic British clinical outcome trial

The Vascular Concepts - PRONOVA Durable Polymer Sirolimus Eluting Stent A Review of Indian Registry Results

Left main coronary artery (LMCA): The proximal segment

PCI for Left Anterior Descending Artery Ostial Stenosis

DRUG-COATED BALLOONS AND CORONARY BIFURCATION LESIONS

IN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014

Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &

The MAIN-COMPARE Study

PROMUS Element Experience In AMC

Left Main Intervention: Will it become standard of care?

DESolve NX Trial Clinical and Imaging Results

DES in Diabetic Patients

Angioplasty Summit TCTAP Technical Aspects of Overview in CTO-PCI Toyohashi Heart Center Takahiko Suzuki, M.D

Drug eluting balloon for bifurcation lesion: is it useful?

Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.

Percutaneous coronary interventions in bifurcation lesions: From theory to practical approach

Transcription:

The Spectrum of Dedicated Stents for Bifurcation Lesions: Current Status and Future Projections Martin B. Leon, MD Columbia University Medical Center Cardiovascular Research Foundation New York City Angioplasty Summit TCT Asia-Pacific 2007 April 25-27, 27, 2007; Seoul, Korea

Presenter Disclosure Information for Angioplasty Summit 2007 Martin B. Leon, M.D. Consultant or Advisory Board: BSC, Cordis-JNJ, Medtronic, Abbott, Cappella, Tryton,, TMI Stockholder or other Equity: Cappella, TMI

Dedicated Bifurcation Stents Classification and Clinical Trends

Medina Bifurcation Classification 0, 1 MB (Distal),, MB (Proximal) SB 0, 1 0, 1 1,1,1 1,1,0 1,0,1 0,1,1 1,0,0 0,1,0 0,0,1

Medina Bifurcation Classification 0, 1 MB (Distal),, MB (Proximal) SB 0, 1 0, 1 17% 9% 18% 13% 1,1,1 1,1,0 1,0,1 0,1,1 17% 14% 12% 1,0,0 0,1,0 0,0,1

Medina Bifurcation Classification MB (Distal),, MB (Proximal) SB 0, 1 0, 1 60% of bifurcation cases 0, 1 17% 18% 13% have disease involvement of the sidebranch! 1,1,1 1,1,0 1,0,1 0,1,1 12% 1,0,0 0,1,0 0,0,1

SIRIUS Bifurcation Study In-lesion Restenosis (treatment received); 78% FU Total Restenosis (MV and/or SB) 25.7% (17/66) 30 25 20 15 10 5 0 Total MV 6.1% (4/66) 6.0 6.2 0 3/50 1/16 12/50 3/16 Main Vessel 30 25 20 15 10 5 Total SB 22.7% (15/66) 24.0 P = 0.74 18.7 Side Branch

SIRIUS Bifurcation Study Restenosis Site (17 cases) Stent + Stent Stent + PTCA *2 11 *1 3 1! 1

DES (Cypher( Cypher) ) drug effects in side branches 30 days after implant (porcine coronaries) Courtesy of: AR Groothuis, ER Edelman, P Seifert, J Dooley, and C Rogers CBSET and Cordis Corporation Main Branch at site of Side Branch origin Side Branch ~1 mm in

NORDIC Bifurcation Trial (SES) Study Design 413 patients with bifurcation lesions (LMCA, LAD. LCx, or RCA) Stenting of both the main vessel and side branch (MV+SB) n=206 pts (95.1% SB stent) Stenting of the main vessel and optional stenting of the side branch (MV only) n=207 pts (4.3% SB stent) Primary Endpoint: Major adverse cardiac event (MACE) at 6 months, defined as cardiac death, myocardial infarction (MI), target lesion revascularization (TLR) or stent thrombosis of the index lesion Steigen T. et al; ACC 2006 Oral Presentation

Nordic Bifurcation RCT 413 pts at 28 centers in 5 countries with true bifurcation received Cypher in main vessels and randomized to PTCA vs. Cypher (crush, culotte, Y or other techniques) of side branch with final kiss. Clinical FU at 6 months. MV stented (%) SB stented (%) Tx successful (%)* N=206 100 4.3 97 N=207 98.5 95.1 95 NS <0.001 Kissing balloon (%) 32 74 <0.001 NS Steigen TC et al. ACC 2006

Nordic Bifurcation Study (n=413) Major Endpoints (clinically driven) 20 18.0 8 In-hospital MI (%) 15 10 5 P=0.01 8.0 6 month MACE (%) 6 4 2 1.0 1.5 1.4 1.0 1.0 Primary endpoint P=0.30 2.5 2.0 1.4 1.4 4.0 4.8 0 0 0 CKMB >3x nl Death MI Stent TLR TVR MACE thrombosis Steigen TC et al. ACC 2006

Dedicated Bifurcation Stents Classification and Clinical Trends There is marked variability in the morphology of coronary bifurcation lesions. The variability includes vessel size (MB and SB), lesion location, eccentricity, length, morphology, and SB takeoff angle. Therefore, multiple strategies may be required to optimally treat highly variable bifurcation lesions.

Dedicated Bifurcation Stents Classification and Clinical Trends Main branch DES do not elicit anti-restenosis responses in covered side branches (requires SB ostial DES coverage). Current clinical trends favor a minimalist single stent approach, but restenosis at the sidebranch ostium remains problematic.

Dedicated Bifurcation Stents Categories of Bifurcation Stents

Dedicated Bifurcation Stents General Categories Complete bifurcation Y stents Sidebranch access MB stents Sidebranch stents Specialty designs (e.g. for LM disease)

Dedicated Bifurcation Stents General Categories Complete bifurcation Y stents Sidebranch access MB stents Sidebranch stents Specialty designs (e.g. for LM disease)

Dedicated Bifurcation Stents Complete Bifurcation Y Stents (1997-present) BARD AVE Guidant Cordis MDT

Dedicated Bifurcation Stents Complete Bifurcation Y Stents The holy grail has been the development of a complete bifurcation Y stent. Thusfar,, many problems have limited clinical progress: system complexity and profile, stent design, wire handling (and wrapping), delivery systems, variable lesion morphologies, AND perceived need. Main use in the future may focus on large vessel bifurcations (LM disease).

Dedicated Bifurcation Stents General Categories Complete bifurcation Y stents Sidebranch access MB stents Sidebranch stents Specialty designs (e.g. for LM disease)

Dedicated Bifurcation Stents Sidebranch Access MB Stents ABT Frontier Invatec Twinrail Minvasys Nile BSC Petal Ymed Sidekick Trireme Medical (TMI) StentYs

ABT Frontier Design Characterisitics Main Branch (RX) Specially designed dual lumen tip Side Branch (OTW) Joining mandrel inserted through OTW inner member Single-Tip Delivery to avoid wire wrap Two Wires maintain access across both branches Kissing Balloon Deployment to minimize plaque shift Provisional T-StentT approach maintains options for additional treatment

ABT Frontier Next Generation DES Main Branch Balloon XIENCETM V Everolimus Coating Side Branch Balloon MULTI-LINK FRONTIERTM DES for Bifurcation MULTI-LINK VISION CoCr Design ML VISIONTM Catheter Side Branch Access CAUTION: XIENCETM V is an investigational device. Limited by Federal (U.S.) law to investigational use only.

Invatec Twin-Rail Design Summary Stent Platform ¾ Closed Cell design ¾ Variable Stent Geometry ¾ Adequate scaffolding of main vessel and side branch ostium Stent Delivery System ¾ Double balloon design SDS Main vessel balloon 3.0mm and 3.5mm Side branch balloon 1.5mm ¾ Double RX design ¾ 6 F Guiding catheter compatible

Minvasys Nile Design Summary One System Two independent catheters Side branch balloon Main branch Balloon + stent + tip

TAXUS Petal Bifurcation Stent Side Branch Lumen (SBL) SBL Marker Bands Side (Petal) Balloon Petal Main Branch Marker Bands Main Branch Stent Main Branch Balloon First Human Use Q2 2007

BSC TAXUS Petal Design Characteristics Delivery System Advantages Side Branch wire lumen aids in alignment at ostium Side branch pre-wired,, no need to re-access through stent Final Petal size determined by post dilatation balloon Stent Advantages Special stent feature to cover ostium of side branch (~2mm) Reduces / eliminates side branch gap and reduce need for 2nd stent Placing 2nd stent, when necessary, is technically straight forward

Y-Med Side-kick Design Charactieristics Low profile system (5 Fr guide compatible) Steerable fixed wire for main branch Rx movable wire for sidebranch access Easily torquable for accurate positioning

Y-Med Side-kick Design Characteristics Mid exit port Steerable fixed wire 5F GC RX side branch protection wire

TriReme Bifurcation Stent Stent Design Design Characteristics Central custom cell with crowns extending into sidebranch ostium upon balloon expansion (ostial( coverage and support) Low profile (6-7Fr guide compatible) Delivery System Rx main branch wire Custom nested side branch wire advanced thru central cell when proximal to side branch Crown markers to assist with axial and rotational alignment

StentYs Bifurcation Stent Design Characteristics 1. Optimal strut selection 2. Disconnection 3. Self-expansion 31

StentYs - Features Anatomical reconstruction of the bifurcation shape Drug-eluting Positioning tolerance (disconnectable struts on full length) Excellent ostium coverage with SB stent Excellent SB access Single wire 5F delivery system Distal MB stented 32